Physician profile
Buntee Co
NPI 1437210796
$2,940.70
in general payments reported to CMS, 2019-2025
16 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $489 · 2021: $279 · 2022: $267 · 2023: $239 · 2024: $562 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.25 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $947.09 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $465.83 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $354.15 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $258.41 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $184.40 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $177.92 | 2019-2020 | |
| Allergan, INC. | $177.44 | 2019-2020 | |
| Axsome Therapeutics, INC. | $140.20 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $97.80 | 2020-2025 | Invega Sustenna |
| Acadia Pharmaceuticals INC | $41.03 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.91 | 2024 | Caplyta |
| Shire North American Group INC | $17.27 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.40 | 2019 | |
| Indivior INC. | $16.03 | 2020 | |
| Lundbeck LLC | $15.44 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buntee Co listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.